BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30950448)

  • 1. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive.
    Ahmed KI; Govardhan HB; Roy M; Naveen T; Siddanna P; Sridhar P; Suma MN; Nelson N
    Indian J Cancer; 2019; 56(1):65-69. PubMed ID: 30950448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
    Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
    Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
    Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
    Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of mutation profiles and tumor mutation burden of cerebrospinal fluid circulating DNA by a cancer genomic panel sequencing in glioma patients.
    Guo W; Jin L; Liang J; Lin G; Zheng J; Zhou D; Zhan S; Sun H; Jiang X
    Clin Chim Acta; 2022 Sep; 534():81-92. PubMed ID: 35810802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
    Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
    Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
    Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
    J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole exome sequencing of cell-free DNA - A systematic review and Bayesian individual patient data meta-analysis.
    Bos MK; Angus L; Nasserinejad K; Jager A; Jansen MPHM; Martens JWM; Sleijfer S
    Cancer Treat Rev; 2020 Feb; 83():101951. PubMed ID: 31874446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and Correlation of Single and Concomitant
    Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
    Okamura R; Piccioni DE; Boichard A; Lee S; Jimenez RE; Sicklick JK; Kato S; Kurzrock R
    Int J Cancer; 2021 Jun; 148(11):2839-2847. PubMed ID: 33497479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
    Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
    J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
    Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
    Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of cell-free DNA in predicting response in adult diffuse glioma on chemoradiotherapy.
    Husain A; Mishra S; Hadi R; Sahu A; Kumari S; Rastogi M; Khurana R; Shukla S; Siddiqui MH; Husain N
    Cancer Genet; 2022 Nov; 268-269():55-63. PubMed ID: 36166960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma.
    Nakagaki T; Tamura M; Kobashi K; Omori A; Koyama R; Idogawa M; Ogi K; Hiratsuka H; Tokino T; Sasaki Y
    Tumour Biol; 2018 Sep; 40(9):1010428318800180. PubMed ID: 30226113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Present and Future of Less-invasive Liquid Biopsy for the Diagnosis of Gliomas and Brain Tumors].
    Natsumeda M; On J; Watanabe J; Tsukamoto Y; Okada M; Fujii Y; Adachi J; Nishikawa R
    No Shinkei Geka; 2021 May; 49(3):527-534. PubMed ID: 34092558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.